Boston Scientific Cuts Medinol Ties With Express2 Stent Approval In U.S.
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will no longer depend on Israeli firm Medinol for its coronary stents in the U.S. after gaining FDA approval of its Express2 stent Sept. 12